AI-generated analysis. Always verify with the original filing.
Envoy Medical, Inc. closed a $30.0 million public offering of 47,946,150 shares of Class A Common Stock (or pre-funded warrants), 45,000,000 Series A-1 Warrants, and 75,000,000 Series A-2 Warrants at $0.40 per share and accompanying warrants on February 12, 2026. The offering provides gross proceeds of $30.0 million upfront and up to $48.0 million more if warrants are exercised, funding FDA pivotal clinical study for Acclaim CI device.
Event Type
Disclosure
Mandatory
Variant
8-K
Entry into a Material Definitive Agreement On February 11, 2026, Envoy Medical, Inc., a Delaware corporation (the “ Company ”), commenced a best efforts public
. Financial Statements and Exhibits. On February 12, 2026, the Company issued a press release announcing the closing of the Offering. A copy of the press releas
Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 4.1 Form of Series A-1 Warrant (incorporated by reference to Exhibit 4.10 to the Form
Material Agreement